Hudson Biotech
CompanyChina
Hudson Biotech develops one asset, in phase 3 (retatrutide in atherosclerotic cardiovascular disease). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in China.
- 1
- Asset
- Furthest stage
- Phase 3
- 2
- Trials
- 9
- Signals
Pipeline
1Activates GLP-1, GIP and glucagon receptors to regulate appetite, glucose metabolism and energy expenditure.
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, atherosclerotic cardiovascular disease, cardiovascular disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms7
- Trials2
- Signals20
- Similar companies6